Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

70 questions · 73 findings · 42 reviews

No studies found 7 · 9.6%GRADE not reported 8 · 11%Very low 20 · 27.4%Low 23 · 31.5%Moderate 14 · 19.2%High 1 · 1.4%

Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone

Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease

Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).

1 finding from 1 review

Long‐acting beta2‐agonist plus tiotropium vs tiotropium

Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease

Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).

1 finding from 1 review

Tiotropium vs ipratropium

Mortality (all‐cause) · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…

Tiotropium showed no clear difference in mortality (all‐cause) compared with ipratropium (moderate certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality · patients with managing pulmonary tuberculosis

The intervention showed no clear difference in all‐cause mortality (low certainty).

1 finding from 1 review

Tiotropium vs long‐acting beta‐agonists

Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease and > 10 pack years smoking history

It is very uncertain whether tiotropium changes mortality (all‐cause) compared with long‐acting beta‐agonists (very low certainty).

1 finding from 1 review

Multi‐component interventions (with telehealth as a component of care) vs usual care

Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with chronic obstructive pulmonary disease

It is very uncertain whether multi‐component interventions (with telehealth as a component of care) changes mortality (all‐cause) overall analysis compared with usual care (very low certainty).

1 finding from 1 review